Lipemia retinalis following FLAG-Ida protocol in an 11-year-old patient with acute myeloid leukemia

被引:0
|
作者
Koruk, Reyhan Hazal Kaplan [1 ]
Kocabora, Mehmet Selim [2 ]
Erdur, Sevil Karaman [2 ]
Yaman, Yontem [3 ]
机构
[1] Istanbul Training & Res Hosp, Dept Ophthalmol, Org Abdurrahman Nafiz Gurman St 24, TR-34098 Istanbul, Turkiye
[2] Istanbul Medipol Univ, Fac Med, Dept Ophthalmol, Istanbul, Turkiye
[3] Istanbul Medipol Univ, Fac Med, Dept Pediat Hematol & Oncol, Istanbul, Turkiye
关键词
Vitreous/retinal disease; PEDIATRIC OPHTHALMOLOGY; pharmacology; PHARMACOLOGY; practice management; SOCIOECONOMICS AND EDUCATION IN MEDICINE/OPHTHALMOLOGY; systemic drug retinal toxicity; RETINA; retinal pathology / research; AML; FLAG-Ida; hypertriglyceridemia; hypercholesterolemia; leukemia; lipemia retinalis;
D O I
10.1177/11206721241287347
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Introduction We report a case of early-onset lipemia retinalis secondary to the FLAG-Ida protocol in the treatment of acute myeloid leukemia (AML) in an 11-year-old girl.Case Report An 11-year-old patient, diagnosed with AML at four months old, experienced a relapse and was treated with the FLAG-Ida protocol (fludarabine, idarubicin, granulocyte-colony stimulating factor, and high-dose cytarabine). Prior to allogeneic stem cell transplantation, she underwent a pre-transplantation eye examination. The patient exhibited normal visual acuity in both eyes. Fundus examination revealed cream-white retinal vessels and a salmon-pink retina, indicative of grade 3 lipemia retinalis. Laboratory tests, normal before treatment initiation, showed significantly elevated serum cholesterol (727.6 mg/dL) and triglyceride (6015.6 mg/dL) levels post-treatment. After receiving fenofibrate, these levels decreased markedly, and the retinal vessels normalized on follow-up fundus examination.Conclusion Lipemia retinalis, characterized by creamy-white retinal vessels resulting from hypertriglyceridemia, can develop as a secondary condition to chemotherapy. Early detection and treatment of hyperlipidemia are crucial to prevent severe ocular and systemic complications. This case highlights the importance of monitoring lipid levels and conducting thorough ophthalmologic examinations in patients undergoing chemotherapy.
引用
收藏
页码:NP5 / NP9
页数:5
相关论文
共 50 条
  • [41] Treatment of Adverse-Risk and Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients with FLAG-IDA ± Venetoclax and CLAG-M: A Monocentric Experience
    Rahme, Ramy
    Vidal, Valerie
    Hueso, Thomas
    Le Meur, Lucie
    Rigal, Marthe
    Ivanoff, Sarah
    Brechignac, Sabine
    De latour, Regis Peffault
    Gardin, Claude
    Braun, Thorsten
    BLOOD, 2023, 142
  • [42] FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk acute myeloid leukemia and myelodysplastic syndromes
    Montesinos, Pau
    de la Rubia, Javier
    Orti, Guillermo
    Sanz, Jaime
    Martinez, David
    Mendoza, Ninotchka
    Scaff, Miguel
    Paciello, Mariliz
    Romero, Monica
    Martin, Guillermo
    Lorenzo, Ignacio
    Martinez, Jesus
    Algarra, Lorenzo
    Jarque, Isidro
    Perez-Sirvent, Mariluz
    Sanz, Guillermo
    Sanz, Miguel A.
    BLOOD, 2007, 110 (11) : 843A - 843A
  • [43] FLAG-IDA Plus Venetoclax in High-Risk Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia: The Princess Margaret Cancer Center Experience
    Al-Shaibani, Eshrak
    Davidson, Marta Beata
    Bankar, Aniket
    Chan, Steven M.
    Sibai, Hassan
    Maze, Dawn C.
    Schimmer, Aaron
    Minden, Mark D.
    Yee, Karen
    Gupta, Vikas
    Schuh, Andre C.
    Richard-Carpentier, Guillaume
    BLOOD, 2024, 144 : 4274 - 4274
  • [44] FOLLOW-UP UPDATE OF THE FLAG-IDA REGIMEN AS BRIDGE THERAPY TO ALLOTRANSPLANTATION IN REFRACTORY/ RELAPSED ACUTE MYELOID LEUKEMIA PATIENTS: 10 YEAR-RESULTS FROM A SINGLE CENTRE EXPERIENCE
    Delia, Mario
    Gagliardi, Vito Pier
    Carluccio, Paola
    Contento, Corinne
    Di Gennaro, Daniela
    Strafella, Wanda
    Attolico, Immacolata
    Albano, Francesco
    Musto, Pellegrino
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 174 - 175
  • [45] Early-onset SMART Syndrome in an 11-Year-old Child With Acute Lymphoblastic Leukemia
    Tsepis, Konstantinos
    Tragiannidis, Athanasios
    Gombakis, Nikolaos
    Hatzistilianou, Maria
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2016, 38 (03) : 248 - 248
  • [46] Venetoclax (VEN) Plus Intensive Chemotherapy (IC) with FLAG-IDA in Patients (Pts) with Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Abaza, Yasmin
    Khan, Talha
    Dinner, Shira
    Frankfurt, Olga
    Altman, Jessica K.
    BLOOD, 2022, 140 : 9036 - 9037
  • [47] Treatment of relapsed and refractory acute myeloid leukemia with a salvage FLAG-IDA chemotherapy regimen followed by a HLA matched related allogeneic PBSC infusion without additional conditioning
    Chandy, Mammen
    Mathews, Vikram
    Rajeskar, T.
    Viswabandya, Auro
    Lakshmi, Kavitha M.
    John, Joseph M.
    George, Biju
    Srivastava, Alok
    BLOOD, 2007, 110 (11) : 342B - 342B
  • [48] A Single Center Retrospective Analysis Comparing the Outcomes of Induction Therapy between 7+3 and FLAG-IDA/Venetoclax in Newly Diagnosed Patients with Acute Myeloid Leukemia
    Abdelmessieh, Peter
    Varshavsky-Yanovsky, Asya
    Shestovska, Yuliya
    Khanal, Rashmi
    Styler, Michael
    Ballas, Brittany
    Ridgway, Forrest
    Sorrentino, Michele
    Ojala, Anne
    Fung, Henry C.
    BLOOD, 2023, 142
  • [49] Long term follow-up of refractory/relapsed acute myeloid leukemia patients treated with the FLAG-Ida regimen as bridge therapy to allotransplantation: 10-year results from a single centre experience
    Delia, Mario
    Gagliardi, Vito Pier
    Carluccio, Paola
    Attolico, Immacolata
    Contento, Corinne
    Di Gennaro, Daniela
    Albano, Francesco
    Musto, Pellegrino
    LEUKEMIA RESEARCH, 2023, 129
  • [50] Seuqential Intensive Chemotherapy (FLAG-IDA) Followed by Reduce-toxicity Conditioning (FLU-BU) for Refractory Acute Myeloid Leukemia: An Interim Analysis of Phase II Trial
    Wang, Ling
    Tang, Wei
    Dou, Han-Bo
    Hu, Jiong
    BLOOD, 2012, 120 (21)